Louis Michaelos, DO
Cornea and External Diseases Specialist · Largo, FLNPI 1326453267
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,863 of the $2,154 with a category attached, or 86.5%. 20 manufacturers reported payments, led by Alcon at 30.4% of the total. Reporting peaked in 2019 at $674 and has fallen 62.7% since, to $251 in 2025.
Across 59 payments — averaging $36.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$655
- Eyevance Pharmaceuticals LLC$292
- Dompe US, Inc.$177
- Bausch & Lomb, A Division Of Bausch Health US, LLC$172
- Sun Pharmaceutical Industries Inc.$149
- Ivantis, Inc$146
- plus $563 from 14 others
What the payments were for
- Travel & lodging$29114%
- Food & beverage$1,86386%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 11 | $655 |
| Eyevance Pharmaceuticals LLC | 5 | $292 |
| Dompe US, Inc. | 3 | $177 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $172 |
| Sun Pharmaceutical Industries Inc. | 7 | $149 |
| Ivantis, Inc | 1 | $146 |
| Kala Pharmaceuticals, Inc. | 5 | $103 |
| Harrow Eye, LLC | 4 | $97 |
| Amgen(2 entities) | 4 | $74 |
| AbbVie(2 entities) | 2 | $55 |
| Novartis | 3 | $52 |
| Akorn, Inc. | 1 | $29 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $25 |
| Biotissue Holdings Inc. | 1 | $25 |
| Oyster Point Pharma, Inc. | 1 | $20 |
| Omeros Corporation | 1 | $18 |
| Bausch & Lomb Americas Inc. | 1 | $18 |
| Sight Sciences, Inc. | 1 | $18 |
| Ocular Therapeutix, Inc. | 1 | $16 |
| Aerie Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIR OPTIX$291
- Hydrus$146
- AcrySof IQ PanOptix$131
- Tobradex ST$122
- Flarex$122
- Oxervate$110
How this compares
Too few cornea and external diseases specialist providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 40 | $22,726 |
| RestasisCyclosporine | 23 | $21,844 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 223 | $15,325 |
| VyzultaLatanoprostene Bunod | 30 | $14,882 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 58 | $14,017 |
| CequaCyclosporine | 16 | $9,147 |
| RhopressaNetarsudil Mesylate | 18 | $7,398 |
| Brimonidine Tartrate | 216 | $5,920 |
| Tobradex StTobramycin/Dexamethasone | 23 | $5,380 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 18 | $4,917 |
| Loteprednol Etabonate | 24 | $4,648 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $4,178 |
| Ketorolac Tromethamine | 84 | $3,714 |
| Alphagan PBrimonidine Tartrate | 12 | $3,527 |
| Prednisolone Acetate | 46 | $2,763 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $55 | $52,27590 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $18 | $14,88230 claims |
| AlconSimbrinza | $655 | $14,01758 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $149 | $9,14716 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $12 | $7,39818 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $292 | $5,38023 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $172 | $4,64824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Largo
- Priya MathewsVenice$358K
- Alfonso SabaterMiami$40K
- Mark HerschelWinter Park$6K
- Leslie GarayOrlando$5K
- Ana Maria OlivaBrandon$5K
- Ansuya DeosaranBoynton Beach$3K
- Malka KirschenbaumBoynton Beach$3K
- Samantha HabhabJacksonville$3K
- Neha ShaikPalm Beach Gardens$2K
- Christopher BarronMelbourne$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.